Your compound through the eyes of the competition
I discuss an experience with helping a company with their need to communicate data effectively in order to differentiate their compound from the standard of care.
I discuss an experience with helping a company with their need to communicate data effectively in order to differentiate their compound from the standard of care.
In this episode, I discuss how you can have an impact on physicians and patients beyond regulatory and HTA approval.
In this episode, we will discuss one-armed observational studies and why they are, in most cases, not a good idea. We will also touch on the early days of my career as a statistician and how I initially approached one-armed observational studies.
In this episode, we discussed RCT Duplicate’s goals and recommendations for real-world evidence researchers based on findings from the initiative.
Anja Schiel – the most recognised regulatory statistician in Europe – and I discuss the potential drawbacks of running single arm studies, as well as ways to balance scientific rigour with feasibility.
In this episode, I’ve gathered up six problems around creating data visualisations, so you can improve the quality of your visualisations.
And it’s almost time for another year and as the New Year brings a lot of challenges, I am excited to share with you my plans and projects for 2023 that you and I both will definitely benefit from.
In this conversation, we talk about the effective impact of the first-mover advantage. To give a more visual distinction of this strategy, it is more like a chess game where the first mover often decides the direction of the game.
In this last part of the leadership series with Gary Sullivan, we talk about the next steps, you can take to work on your leadership skills.
In this episode, we have our first non-statistician as a guest. Julia has built her own consulting and training company Zestfor.